Sunshine Biopharma Q2 2023 revenues jump 3,600% YoY to $5.56M

Sunshine Biopharma Inc.

Revenues of $5,560,865 for Q2 2023, a 3,600% increase over Q2 2022.
Revenue growth driven by Nora Pharma generic drug sales, acquired Oct 2022.
Q2 2023 revenues up 13.6% sequentially from Q1 2023.
CEO Dr. Steve Slilaty expressed optimism for continued growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sunshine Biopharma Inc. reported the 2023 second quarter results: revenue $5,560,865.

Period: the 2023 second quarter
Revenue: $5,560,865
Result: reported results

Exact text from the filing

of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 second quarter. The Company reported gross revenues of $5,560,865 for the quarter ended June 30, 2023, an increase of 3,600% over the same period in 2022. The increase was largely due to the prescription drugs sales of Nora Pharma Inc., a

View on SEC.gov

Browse all earnings releases →

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-005540

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.